|Ms. Vered Caplan||Chairman, CEO & Pres||656.82k||N/A||1969|
|Prof. Sarah Ferber||Founder & Chief Scientific Officer||268.32k||N/A||1954|
|Mr. Neil T. Reithinger||CFO, Sec. & Treasurer||266.45k||N/A||1970|
|Dr. Denis Bedoret||Managing Director of MaSTherCell||268.39k||N/A||1981|
Orgenesis Inc., a biotechnology company, engages in the development, manufacturing, and provision of services in the cell and gene therapy industry. The CDMO segment specializes in therapy development services, such as manufacturing and development services, and contract manufacturing services. The PT Business segment focuses on the development of proprietary cell and gene therapies, including the autologous trans-differentiation technology. It also has various collaboration and license agreements with Adva Biotechnology Ltd.; Tel Hashomer Medical Research, Infrastructure and Services Ltd; Mircod Limited; HekaBio K.K; Image Securities Ltd.; Hemogenyx Pharmaceuticals PLC.; Immugenyx LLC.; BG Negev Technologies and Applications; and Columbia University. The company was formerly known as Business Outsourcing Services, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was founded in 2008 and is based in Germantown, Maryland.
Orgenesis Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.